| Literature DB >> 27646833 |
Jukka Kuusela1,2, Jiyeong Kim3, Esa Räsänen3, Katriina Aalto-Setälä4,5,6,7.
Abstract
Healthy human heart rate fluctuates overtime showing long-range fractal correlations. In contrast, various cardiac diseases and normal aging show the breakdown of fractal complexity. Recently, it was shown that human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) intrinsically exhibit fractal behavior as in humans. Here, we investigated the fractal complexity of hiPSC-derived long QT-cardiomyocytes (LQT-CMs). We recorded extracellular field potentials from hiPSC-CMs at baseline and under the effect of various compounds including β-blocker bisoprolol, ML277, a specific and potent IKs current activator, as well as JNJ303, a specific IKs blocker. From the peak-to-peak-intervals, we determined the long-range fractal correlations by using detrended fluctuation analysis. Electrophysiologically, the baseline corrected field potential durations (cFPDs) were more prolonged in LQT-CMs than in wildtype (WT)-CMs. Bisoprolol did not have significant effects to the cFPD in any CMs. ML277 shortened cFPD in a dose-dependent fashion by 11 % and 5-11 % in WT- and LQT-CMs, respectively. JNJ303 prolonged cFPD in a dose-dependent fashion by 22 % and 7-13 % in WT- and LQT-CMs, respectively. At baseline, all CMs showed fractal correlations as determined by short-term scaling exponent α. However, in all CMs, the α was increased when pharmacological compounds were applied indicating of breakdown of fractal complexity. These findings suggest that the intrinsic mechanisms contributing to the fractal complexity are not altered in LQT-CMs. The modulation of IKs channel and β1-adrenoreceptors by pharmacological compounds may affect the fractal complexity of the hiPSC-CMs.Entities:
Keywords: Cardiomyocytes; Detrended fluctuation analysis; Fractals; Induced pluripotent stem cell; Long QT syndrome; Multielectrode array; Nonlinear dynamics
Mesh:
Substances:
Year: 2016 PMID: 27646833 PMCID: PMC5106508 DOI: 10.1007/s12015-016-9686-0
Source DB: PubMed Journal: Stem Cell Rev Rep ISSN: 2629-3277 Impact factor: 5.739
Fig. 1The effects of various compounds to the human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes’ field potential parameters. The upper row depicts the beating rate (BR) and the lower row Fridericia-corrected field potential duration (cFPD). The baseline cFPDs of long QT-specific cardiomyocytes were significantly more prolonged than in healthy wild type-cardiomyocytes. The asterisks on top of the bars depict the statistical significance for mean BR or cFPD change compared to baseline values. Significance levels are indicated by (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001, respectively
Fig. 2The representative traces of the human induced pluripotent stem cell (hiPSC)-derived wild type- and long QT (LQT)-specific cardiomyocytes under the effect of various compounds. The LQTs are grouped according to symptomatic (208.LQT1, 211.LQT1) and asymptomatic cases (303.LQT1, 313.LQT1) shown in the middle and in the right column, respectively. a) β-blocker Bisoprolol, b) IKs activator ML277 c) IKs blocker JNJ303. Notice, how the Tmax of the repolarization wave is relatively unchanged between baseline and different bisoprolol concentrations depicting marginal effect of the β-blocker to the corrected field potential duration (cFPD). However, IKs activator ML277 shows clear shortening of cFPD seen by shift in the Tmax. Similarly, but conversely to ML277, IKs blocker JNJ303 shows clear prolongation of cFPD assessed by the shift in the Tmax
The patient characteristics and detrended fluctuation analysis from ECG data
| Healthy individual | LQT1-patient (symptomatic) | LQT1-patient (asymptomatic) | |
|---|---|---|---|
| Age | 55 | 41 | 28 |
| Medication | - | Bisoprolol | Bisoprolol |
| QTc (ms) | 406 | 456 | 428 |
| α | 1.21 ± 0.03 | 1.08 ± 0.02 | 1.07 ± 0.02 |
Fig. 3The detrended fluctuation analysis (DFA) α scaling exponents of the human induced pluripotent stem cell (hiPSC)-derived wild type- and long QT (LQT)-specific cardiomyocytes. The LQTs are grouped according to symptomatic (208.LQT1, 211.LQT1) and asymptomatic cases (303.LQT1, 313.LQT1) shown in the middle and in the right column, respectively. a) (row) β-blocker Bisoprolol, b) IKs activator ML277 c) IKs blocker JNJ303. At baseline, the α scaling exponents are close to 1 in all hiPSC-CMs. The addition of various compounds to the hiPSC-CMs increased the α scaling exponent closer to Brownian motion (α = 1.5). The asterisks on top of the bars depict the statistical significance for mean α scaling exponent change compared to baseline values. Significance levels are indicated by (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001, respectively